For example, in a double-blind, randomized, placebo-controlled phase 3 clinical trial named VALOR (NCT02623699), the efficacy and safety of the SOD1-targeting ASO, tofersen, was tested in symptomatic patients with SOD1 ALS [64]. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.